View in EDS HTML Full Text PDF Full Text

Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.

Saved in:
Bibliographic Details
Title: Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Authors: Reyes DK; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. dreyes@jhmi.edu., Trock BJ; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Tran PT; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Pavlovich CP; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Deville C; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Allaf ME; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Greco SC; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Song DY; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bivalacqua TJ; Department of Surgery, Division of Urology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Han M; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Partin AW; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sartor AO; Department of Oncology, Tulane Cancer Center, Tulane University, New Orleans, LA, USA., Rowe SP; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Pienta KJ; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Source: Medical oncology (Northwood, London, England) [Med Oncol] 2022 Apr 28; Vol. 39 (5), pp. 63. Date of Electronic Publication: 2022 Apr 28.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35478055
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Reyes+DK%22">Reyes DK</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. dreyes@jhmi.edu.<br /><searchLink fieldCode="AU" term="%22Trock+BJ%22">Trock BJ</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Tran+PT%22">Tran PT</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Pavlovich+CP%22">Pavlovich CP</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Deville+C%22">Deville C</searchLink>; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Allaf+ME%22">Allaf ME</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Greco+SC%22">Greco SC</searchLink>; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Song+DY%22">Song DY</searchLink>; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Bivalacqua+TJ%22">Bivalacqua TJ</searchLink>; Department of Surgery, Division of Urology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Han+M%22">Han M</searchLink>; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Partin+AW%22">Partin AW</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Sartor+AO%22">Sartor AO</searchLink>; Department of Oncology, Tulane Cancer Center, Tulane University, New Orleans, LA, USA.<br /><searchLink fieldCode="AU" term="%22Rowe+SP%22">Rowe SP</searchLink>; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Pienta+KJ%22">Pienta KJ</searchLink>; The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229435512%22">Medical oncology (Northwood, London, England)</searchLink> [Med Oncol] 2022 Apr 28; Vol. 39 (5), pp. 63. <i>Date of Electronic Publication: </i>2022 Apr 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9435512 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1559-131X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213570560%22">13570560 </searchLink><i>NLM ISO Abbreviation: </i>Med Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35478055
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12032-022-01662-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 63
    Titles:
      – TitleFull: Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Reyes DK
      – PersonEntity:
          Name:
            NameFull: Trock BJ
      – PersonEntity:
          Name:
            NameFull: Tran PT
      – PersonEntity:
          Name:
            NameFull: Pavlovich CP
      – PersonEntity:
          Name:
            NameFull: Deville C
      – PersonEntity:
          Name:
            NameFull: Allaf ME
      – PersonEntity:
          Name:
            NameFull: Greco SC
      – PersonEntity:
          Name:
            NameFull: Song DY
      – PersonEntity:
          Name:
            NameFull: Bivalacqua TJ
      – PersonEntity:
          Name:
            NameFull: Han M
      – PersonEntity:
          Name:
            NameFull: Partin AW
      – PersonEntity:
          Name:
            NameFull: Sartor AO
      – PersonEntity:
          Name:
            NameFull: Rowe SP
      – PersonEntity:
          Name:
            NameFull: Pienta KJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2022 Apr 28
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1559-131X
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Medical oncology (Northwood, London, England)
              Type: main
ResultId 1